Mechanisms of cachexia in chronic disease states

American Journal of the Medical Sciences

Volumn 350, Issue 4, 2015, Pages 250-256

  Yoshida, Tadashi ^a   Delafontaine, Patrice ^a  

^a University of Missouri   (United States)

Author keywords

Angiotensin II; Cachexia; Muscle wasting; Skeletal muscle

Indexed keywords

AMYLOID A PROTEIN; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ATROGIN 1; INTERLEUKIN 6; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; MUSCLE PROTEIN; PROTEASOME; PROTEIN; UBIQUITIN;

ARTICLE; CACHEXIA; CELL DIFFERENTIATION; CELL PROLIFERATION; CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; DECREASED APPETITE; ENERGY BALANCE; FOOD INTAKE; HUMAN; MUSCLE ATROPHY; MUSCLE REGENERATION; MUSCLE STEM CELL; NONHUMAN; OXIDATIVE STRESS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SKELETAL MUSCLE; SKELETAL MUSCLE SATELLITE CELL; WEIGHT REDUCTION; ANIMAL; CHEMISTRY; DRUG EFFECTS; METABOLISM; MUSCLE; PATHOLOGY; REGENERATION; SIGNAL TRANSDUCTION;

ANGIOTENSIN II; ANIMALS; CACHEXIA; CELL PROLIFERATION; CHRONIC DISEASE; CYTOKINES; HUMANS; MUSCLE PROTEINS; MUSCLES; MUSCULAR ATROPHY; OXIDATIVE STRESS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEINS; REGENERATION; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION; UBIQUITIN;

EID: 84942790073     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0000000000000511     Document Type: Article

References (94)

1. Morley JE, Thomas DR, Wilson MMG. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 2006;83:735-43.
2. Oliff A, Defeo-Jones D, Boyer M, et al. Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 1987;50:555-63.
3. Li YP, Chen Y, John J, et al. TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J 2005;19:362-70.
4. Llovera M, García-Martínez C, López-Soriano J, et al. Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice. Mol Cell Endocrinol 1998;142:183-9.
5. Maltoni M, Fabbri L, Nanni O, et al. Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients. Support Care Cancer 1997;5:130-5.
6. Jatoi A, Ritter HL, Dueck A, et al. A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer 2010;68:234-9.
7. Scott HR, McMillan DC, Crilly A, et al. The relationship between weight loss and interleukin 6 in non-small-cell lung cancer. Br J Cancer 1996;73:1560-2.
8. Moses AGW, Maingay J, Sangster K, et al. Pro-inflammatory cytokine release by peripheral blood mononuclear cells from patients with advanced pancreatic cancer: Relationship to acute phase response and survival. Oncol Rep 2009;21:1091-5.
9. Strassmann G, Fong M, Kenney JS, et al. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 1992;89:1681-4.
10. Bayliss TJ, Smith JT, Schuster M, et al. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol 2011;11:1663-8.
11. Han HQ, Zhou X, Mitch WE, et al. Myostatin/activin pathway antagonism: molecular basis and therapeutic potential. Int J Biochem Cell Biol 2013;45:2333-47.
12. Mosher DS, Quignon P, Bustamante CD, et al. A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. Plos Genet 2007;3:e79.
13. SchuelkeM, Wagner KR, Stolz LE, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Eng J Med 2004;350:2682-8.
14. Trendelenburg AU, Meyer A, Jacobi C, et al. TAK-1/p38/nNFkB signaling inhibits myoblast differentiation by increasing levels of Activin A. Skeletal Muscle 2012;2:3.
15. Zhou X, Wang JL, Lu J, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010; 142:531-43.
16. Cohen S, Nathan JA, Goldberg AL. Muscle wasting in disease: molecular mechanisms and promising therapies. Nat Rev Drug Discov 2015;14:58-74.
17. Anker SD, Volterrani M, Pflaum CD, et al. Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J Am Coll Cardiol 2001;38:443-52.
18. Suskin N, McKelvie RS, Burns RJ, et al. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J 2000;21:1368-75.
19. Wei Y, Sowers JR, Clark SE, et al. Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase. Am J Physiol Endocrinol Metab 2008;294:E345-51.
20. Csibi A, Communi D, Müller N, et al. Angiotensin II inhibits insulinstimulated GLUT4 translocation and Akt activation through tyrosine nitration-dependent mechanisms. PLoS One 2010;5:e10070.
21. Anker SD, Negassa A, Coats AJS, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: An observational study. Lancet 2003;361:1077-83.
22. Schellenbaum GD, Smith NL, Heckbert SR, et al. Weight loss, muscle strength, and angiotensin-converting enzyme inhibitors in older adults with congestive heart failure or hypertension. J Am Geriatr Soc 2005;53:1996-2000.
23. Di Bari M, van de Poll-Franse LV, Onder G, et al. Antihypertensive medications and differences in muscle mass in older persons: The Health, Aging and Body Composition Study. J Am Geriatr Soc 2004;52:961-6.
24. Paolisso G, Balbi V, Gambardella A, et al. Lisinopril administration improves insulin action in aged patients with hypertension. J Hum Hypertens 1995;9:541-6.
25. Schanze N, Springer J. Evidence for an effect of ACE inhibitors on cancer cachexia. J Cachexia Sarcopenia Muscle 2012;3:139-9.
26. Osherovich L. New muscle for ARB strategy. SciBX: Acience-business exchange. Nat Publishing Group 2011;4:1-2.
27. Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J Intern Med 2008;264:224-36.
28. Brink M, Wellen J, Delafontaine P. Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J Clin Invest 1996;97:2509-16.
29. Ventadour S, Attaix D. Mechanisms of skeletal muscle atrophy. Curr Opin Clin Nutr Metab Care 2006;18:631-5.
30. Bodine SC, Latres E, Baumhueter S, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001;294:1704-8.
31. Song YH, Li Y, Du J, et al. Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest Am Soc Clin Invest 2005;115:451-8.
32. Yoshida T, Semprun-Prieto L, Sukhanov S, et al. IGF-1 prevents ANG II-induced skeletal muscle atrophy via Akt- And Foxodependent inhibition of the ubiquitin ligase atrogin-1 expression. Am J Physiol Heart Circ Physiol 2010;298:H1565-70.
33. Semprun-Prieto LC, Sukhanov S, Yoshida T, et al. Angiotensin II induced catabolic effect and muscle atrophy are redox dependent. Biochem Biophys Res Comm 2011;409:217-21.
34. Brink M, Price SR, Chrast J, et al. Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I. Endocrinology 2001;142:1489-96.
35. Sandri M. Signaling in muscle atrophy and hypertrophy. Physiology (Bethesda) 2008;23:160-70.
36. Bodine SC, Stitt TN, Gonzalez M, et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 2001;3:1014-9.
37. Rommel C, Bodine SC, Clarke BA, et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3) K/Akt/GSK3 pathways. Nat Cell Biol 2001;3:1009-13.
38. Peng XD, Xu PZ, Chen ML, et al. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev 2003;17:1352-65.
39. Pallafacchina G, Calabria E, Serrano AL, et al. A protein kinase Bdependent and rapamycin-sensitive pathway controls skeletal muscle growth but not fiber type specification. Proc Natl Acad Sci U S A 2002;99:9213-8.
40. Musaro A, McCullagh K, Paul A, et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 2001;27:195-200.
41. Attaix D, Baracos VE. MAFbx/Atrogin-1 expression is a poor index of muscle proteolysis. Curr Opin Clin Nutr Metab Care 2010;13:223-4.
42. Clarke BA, Drujan D, Willis MS, et al. The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab 2007;6:376-85.
43. Cohen S, Brault JJ, Gygi SP, et al. During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J Cell Biol 2009;185:1083-95.
44. Tintignac LA, Lagirand J, Batonnet S, et al. Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase. J Biol Chem 2005;280: 2847-56.
45. Lagirand-Cantaloube J, Offner N, Csibi A, et al. The initiation factor eIF3-f is a major target for Atrogin1/MAFbx function in skeletal muscle atrophy. EMBO J 2008;27:1266-76.
46. McLoughlin TJ, Smith SM, DeLong AD, et al. FoxO1 induces apoptosis in skeletal myotubes in a DNA-binding-dependent manner. Am J Physiol Cell Physiol 2009;297:C548-55.
47. Senf SM, Dodd SL, Judge AR. FOXO signaling is required for disuse muscle atrophy and is directly regulated by Hsp70. Am J Physiol Cell Physiol 2010;298:C38-C45.
48. Sanders PM, Russell ST, Tisdale MJ. Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia. Br J Cancer 2005;93:425-34.
49. Russell ST, Sanders PM, Tisdale MJ. Angiotensin II directly inhibits protein synthesis in murine myotubes. Cancer Lett 2006;231:290-4.
50. Zhang L, Du J, Hu Z, et al. IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. J Am Soc Nephrol 2009;20:604-12.
51. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: Role in cardiovascular biology and disease. Circ Res 2000;86:494-501.
52. Manrique C, Lastra G, Gardner M, et al. The renin angiotensin aldosterone system in hypertension: Roles of insulin resistance and oxidative stress. Med Clin North Am 2009;93:569-82.
53. Zhao W, Swanson SA, Ye J, et al. Reactive oxygen species impair sympathetic vasoregulation in skeletal muscle in angiotensin IIdependent hypertension. Hypertension 2006;48:637-43.
54. Wei Y, Sowers JR, Nistala R, et al. Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells. J Biol Chem 2006;281:35137-46.
55. Powers SK, Wiggs MP, Duarte JA, et al. Mitochondrial signaling contributes to disuse muscle atrophy. Am J Physiol Endocrinol Metab 2012;303:E31-9.
56. Muller FL, Song W, Jang YC, et al. Denervation-induced skeletal muscle atrophy is associated with increased mitochondrial ROS production. Am J Physiol Regul Integr Comp Physiol 2007;293: R1159-68.
57. Whitehead NP, Yeung EW, Froehner SC, et al. Skeletal muscle NADPH oxidase is increased and triggers stretch-induced damage in the mdx mouse. PLoS One 2010;5:e15354.
58. Pueyo ME, Gonzalez W, Nicoletti A, et al. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 2000;20:645-51.
59. Kimura B, Sumners C, Phillips MI. Changes in skin angiotensin II receptors in rats during wound healing. Biochem Biophys Res Comm 1992;187:1083-90.
60. Tabony AM, Yoshida T, Galvez S, et al. Angiotensin II upregulates protein phosphatase 2Ca and inhibits AMP-activated protein kinase signaling and energy balance leading to skeletal muscle wasting. Hypertension 2011;58:643-9.
61. Lecker SH, Jagoe RT, Gilbert A, et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 2004;18:39-51.
62. Aguilar V, Alliouachene S, Sotiropoulos A, et al. S6 kinase deletion suppresses muscle growth Adaptations to nutrient availability by activating AMP kinase. Cell Metab 2007;5:476-87.
63. Nakashima K, Yakabe Y. AMPK activation stimulates myofibrillar protein degradation and expression of atrophy-related ubiquitin ligases by increasing FOXO transcription factors in C2C12 myotubes. Biosci Biotechnol Biochem 2007;71:1650-6.
64. Tabony AM, Yoshida T, Sukhanov S, et al. Protein phosphatase 2Calpha knockdown reduces angiotensin II-mediated skeletal muscle wasting via restoration of mitochondrial recycling and function. Skeletal Muscle 2014;4:20.
65. Evans WJ, Morley JE, Argilés J, et al. Cachexia: A new definition. Clin Nutr 2008;27:793-9.
66. Fouladiun M, Körner U, Bosaeus I, et al. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care-correlations with food intake, metabolism, exercise capacity, and hormones. Cancer 2005;103: 2189-98.
67. Porter JP, Anderson JM, Robison RJ, et al. Effect of central angiotensin II on body weight gain in young rats. Brain Res 2003;959:20-8.
68. Porter JP, Potratz KR. Effect of intracerebroventricular angiotensin II on body weight and food intake in adult rats. Am J Physiol Regul Integr Comp Physiol 2004;287:R422-8.
69. De-Kloet AD, Krause EG, Scott KA, et al. Central angiotensin-II has catabolic action at white and brown adipose tissue. Am J Physiol Endocrinol Metab 2011;301(6):E1081-91.
70. Yoshida T, Semprun-Prieto L, Wainford RD, et al. Angiotensin II reduces food intake by altering orexigenic neuropeptide expression in the mouse hypothalamus. Endocrinology 2012;153:1411-20.
71. Lenkei Z, Palkovits M, Corvol P, et al. Expression of angiotensin type-1 (AT1) and type-2 (AT2) receptor mRNAs in the adult rat brain: A functional neuroanatomical review. Front Neuroendocrinol 1997;18: 383-439.
72. Yablonka-Reuveni Z, Day K. Skeletal muscle stem cells in the spotlight: The satellite cell. In: Cohen IS, Gaudette GR, editors. Regenerating the heart. Springer, New York, New York; 2011. pp. 173-200.
73. Mehl KA, Davis JM, Berger FG, et al. Myofiber degeneration/regeneration is induced in the cachectic ApcMin/+ mouse. J Appl Physiol (1985) 2005;99:2379-87.
74. Penna F, Costamagna D, Fanzani A, et al. Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition. PLoS One 2010;5:e13604.
75. Costelli P, Muscaritoli M, Bossola M, et al. Skeletal muscle wasting in tumor-bearing rats is associated with MyoD down-regulation. Int J Oncol 2005;26:1663-8.
76. Conboy IM, Conboy MJ, Smythe GM, et al. Notch-mediated restoration of regenerative potential to aged muscle. Science 2003;302: 1575-7.
77. Chakkalakal JV, Jones KM, Basson MA, et al. The aged niche disrupts muscle stem cell quiescence. Nature 2012;490:355-60.
78. Conboy IM, Rando TA. The regulation of Notch signaling controls satellite cell activation and cell fate determination in postnatal myogenesis. Dev Cell. 2002;3:397-409.
79. Carlson ME, Hsu M, Conboy IM. Imbalance between pSmad3 and Notch induces CDK inhibitors in old muscle stem cells. Nature 2008; 454:528-32.
80. Conboy IM, Conboy MJ, Wagers AJ, et al. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature 2005;433:760-4.
81. Sinha M, Jang YC, Oh J, et al. Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. Science 2014;344:649-52.
82. Argilés JM, López-Soriano FJ, Busquets S. Novel approaches to the treatment of cachexia. Drug Discov Today 2008;13:73-8.
83. Doehner W, Haehling von S, Anker SD, et al. Neurohormonal activation and inflammation in chronic cardiopulmonary disease: A brief systematic review. Wien Klin Wochenschr 2009;121:293-6.
84. Haehling von S, Lainscak M, Springer J, et al. Cardiac cachexia: A systematic overview. Pharmacol Ther 2009;121:227-52.
85. Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev 2009;89: 381-410.
86. Cohn RD, van Erp C, Habashi JP, et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 2007;13:204-10.
87. Bedair HS, Karthikeyan T, Quintero A, et al. Angiotensin II receptor blockade administered after injury improves muscle regeneration and decreases fibrosis in normal skeletal muscle. Am J Sports Med 2008;36: 1548-54.
88. Burks TN, Andres-Mateos E, Marx R, et al. Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia. Sci Transl Med 2011;3:82ra37.
89. Johnston APW, Baker J, Bellamy LM, et al. Regulation of muscle satellite cell activation and chemotaxis by angiotensin II. PLoS One 2010;5:e15212.
90. Murphy KT, Allen AM, Chee A, et al. Disruption of muscle reninangiotensin system in AT1a-/- mice enhances muscle function despite reducing muscle mass but compromises repair after injury. Am J Physiol Regul Integr Comp Physiol 2012;303:R321-31.
91. Yoshida T, Galvez S, Tiwari S, et al. Angiotensin II inhibits satellite cell proliferation and prevents skeletal muscle regeneration. J Biol Chem 2013;288:23823-32.
92. Yoshida T, Huq TS, Delafontaine P. Angiotensin type 2 receptor signaling in satellite cells potentiates skeletal muscle regeneration. J Biol Chem 2014;289:26239-48.
93. Berk BC. Angiotensin type 2 receptor (AT2R): A challenging twin. Sci STKE 2003;2003:PE16.
94. Acuna MJ, Pessina P, Olguin H, et al. Restoration of muscle strength in dystrophic muscle by angiotensin-1-7 through inhibition of TGFsignalling. Hum Mol Genet 2014;23:1237-49.